Eliminating hearing loss as a chronic condition

Rescue Hearing’s initial gene therapy product will target a genetic mutation known to cause progressive hearing loss which eventually leads to deafness.

Did you know?

466 million people in the world live with disabling hearing loss – 6.1% of the world’s population according to the World Health Organization.

Press Release

May 20th, 2022

Rescue Hearing set to Enter into a Worldwide Exclusive License Agreement with Myrtelle!

About Us

RESCUE HEARING

RHI has assembled a team of visionary, internationally recognized physicians, scientists, and bioengineers who share a common passion for developing therapies for humans suffering from hearing loss. The team is developing therapeutic and diagnostic platforms that will address the most difficult hearing loss indications.

Dr. Hinrich Staecker

Pioneer

RHI CSO Dr. Hinrich Staecker is the pioneer of gene therapy for hearing loss as the PI and inventor of the only gene therapy for hearing loss approved for human clinical trial (CGF-166 Novartis).

About Us

RESCUE HEARING

RHI has assembled a team of visionary, internationally recognized physicians, scientists, and bioengineers who share a common passion for developing therapies for humans suffering from hearing loss. The team is developing therapeutic and diagnostic platforms that will address the most difficult hearing loss indications.

First product

RHI100

Targets individuals born with progressive hearing loss. 

Revenue Potential

RHI100 is a multi-billion-dollar asset (Peak revenue 2032).

Development Phase

RHI100 is currently in the pre-IND studies phase.

Patent Protection

RHI100 has worldwide patent protection
through 2041.

Stay up to date with RHI

Connect with us on LinkedIn and follow our Twitter
for updates and exciting progress

Announcements

Latest News

Show All news

Subscribe to our newsletter for
the latest news & updates

Subscribe to our newsletter for the latest news & updates